Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The study evaluates efficacy of Ridaforolimus when administered as maintenance therapy to
patients with metastatic bone or soft-tissue sarcoma in Japan.